Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium

Current Eye Research

Volumn 35, Issue 1, 2010, Pages 17-22

  Fallah, Mohammad Reza ^a   Khosravi, Keivan ^a   Hashemian, Mohammad Nasser ^a   Beheshtnezhad, Amir Hoshang ^a   Rajabi, Mohammad Taher ^a   Gohari, Mohsen ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Impending recurrent pterygium; Pterygium; Topical bevacizumab

Indexed keywords

BETAMETHASONE; BEVACIZUMAB; MITOMYCIN C;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FIBROBLAST; FOLLOW UP; HUMAN; IMPENDING RECURRENT PTERYGIUM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; PTERYGIUM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BETAMETHASONE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PTERYGIUM; RECURRENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73649130636     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903395273     Document Type: Article

References (37)

1. Cheng HC, Tseng SH, Kao PL, et al. Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery. Cornea 2001;20:24-29.
2. Rodriguez JA, Ferrari C, Hernández GA. Intraoperative application of topical mitomycin C 0.05% for pterygium surgery. Bol Assoc Med P R 2004;96:100-102.
3. Rahman A, Yahya K, Ul Hasan KS. Recurrence rate of pterygium following surgical excision with intraoperative versus postoperative mitomycin-C. J Coll Physicians Surg Pak 2008;18:489-492.
4. Varssano D, Michaeli-Cohen A, Loewenstein A. Excision of pterygium and conjunctival autograft. Isr Med Assoc J 2002;4:1097-1100.
5. Bahar I, Kaiserman I, Weisbrod M, et al. Extensive versus limited pterygium excision with conjunctival autograft: Outcomes and recurrence rates. Curr Eye Res 2008;33: 435-440.
6. Liu S, Peng H, Liu Y, et al. Amniotic membrane transplantation and limbal autograft transplantation for patients with recurrent pterygium. Yan Ke Xue Bao 2007;23:227-230.
7. Jain AK, Bansal R, Sukhija J. Human amniotic membrane transplantation with fibrin glue in management of primary pterygia: A new tuck-in technique. Cornea 2008;27:94-99.
8. Vastine DW, Stewart WB, Schwab IR. Reconstruction of the periocular mucous membrane by autologous conjunctival transplantation. Ophthalmology 1982;89:1072-1081.
9. Isohashi F, Inoue T, Xing S, et al. Postoperative irradiation for pterygium: Retrospective analysis of 1253 patients from the Osaka University Hospital. Strahlenther Onkol 2006;182:437-442.
10. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006;113:1102-1109.
11. Pherwani A, Vakil V, Eatamadi H, et al. Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium. Br J Ophthalmol 2007;91:398-399.
12. Bekibele CO, Baiyeroju AM, Olusanya BA, et al. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye 2008;22:31-34.
13. Ioachim-Velogianni E, Tsironi E, Agnantis N, et al. HLA-DR antigen expression in pterygium epithelial cells and lymphocyte subpopulations: An immunohistochemistry study. Ger J Ophthalmol 1995;4:123-129.
14. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001; 20:738-742.
15. Marcovich AL, Morad Y, Sandbank J, et al. Angiogenesis in pterygium: Morphometric and immunohistochemical study. Curr Eye Res 2002;25:17-22.
16. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium- derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003;22: 473-477.
17. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 2005;112: 1023-1030.
18. Yan M, Li Z, Liu G, et al. Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium. Yan Ke Xue Bao 2007;23:20-24.
19. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 2007;21: 1095-1101.
20. Lee JK, Song YS, Ha HS, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye 2007;21:1186-1193.
21. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
22. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335.
23. Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handbook Exp Pharmacol 2008;181:131-150.
24. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson Syndrome. Cornea 2008;27:70-73.
25. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38.
26. Yoeruek E, Ziemssen F, Henke-Fahle S, et al; Tübingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eye drops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008;86:322-328.
27. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807.
28. Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology 1997;104:974-985.
29. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745-748.
30. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007;69:925-927.
31. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33: 23-28. (Pubitemid 351156952)
32. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea 2009;28: 468-470.
33. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-389.
34. Nomoto H, Shiraga F, Kuno N, et al. pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50(10):4807-4813.
35. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009;50:2095-2102.
36. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247(10):1375-1382.
37. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eye drops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009;28: 103-104.